Anti-reflux medication use in preterm infants

Binti Abdul Hamid H 1 , Szatkowski L 1 , Budge H 1 , Ojha S 2

Affiliations 

  • 1 Population and Lifespan Sciences, School of Medicine, University of Nottingham, Nottingham, UK
  • 2 Population and Lifespan Sciences, School of Medicine, University of Nottingham, Nottingham, UK. shalini.ojha@nottingham.ac.uk
Pediatr Res, 2021 Oct 29.
PMID: 34716422 DOI: 10.1038/s41390-021-01821-y

Abstract

BACKGROUND: Current recommendations do not support the use of anti-reflux medications to treat gastro-oesophageal reflux disease (GORD) among preterm infants.

OBJECTIVE: To describe the prevalence of GORD and the use of anti-reflux medications amongst very preterm infants (<32 weeks' gestational age (GA)) in neonatal units in England and Wales.

DESIGN: Retrospective cohort study using the National Neonatal Research Database.

RESULTS: Among 58,108 infants [median GA (IQR) 29 (27-30) weeks], 15.8% (n = 9191) had a diagnosis of GORD and 36.9% (n = 12,446) received anti-reflux medications. Those who received anti-reflux medications were more preterm [GA, median (IQR): medications, 28 (26-30) vs. no medications, 30 (28-31); p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications